{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:34:36Z","timestamp":1792661676106,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["CSAINV21nov-0003"],"award-info":[{"award-number":["CSAINV21nov-0003"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.nmni.2024.101533","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T21:17:49Z","timestamp":1731705469000},"page":"101533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Risk of tuberculosis disease in patients receiving TNF-\u03b1 antagonist therapy: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"62","author":[{"given":"Fatemeh","family":"Khelghati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Rahmanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Eghbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Sadat","family":"Seghatoleslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Goudarzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliasghar","family":"Keramatinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine WM.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Goletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"D'Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Centis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3279-0671","authenticated-orcid":false,"given":"Mohammad Javad","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmni.2024.101533_bib1","series-title":"Global tuberculosis report 2022","author":"Organization","year":"2022"},{"key":"10.1016\/j.nmni.2024.101533_bib2","article-title":"Delamanid and bedaquiline resistance patterns in Mycobacterium tuberculosis in Iran: a cross-sectional analysis","author":"Aghababa","year":"2024","journal-title":"New Microb New Infecti"},{"key":"10.1016\/j.nmni.2024.101533_bib3","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.nmni.2024.101533_bib4","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.nmni.2024.101533_bib5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/rheumatology\/key364","article-title":"Risk of tuberculosis in patients with immune-mediated diseases on biological therapies: a population-based study in a tuberculosis endemic region","volume":"58","author":"Wang","year":"2019","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.nmni.2024.101533_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2022.102202","article-title":"Tuberculosis and autoimmunity: common features","volume":"134","author":"Starshinova","year":"2022","journal-title":"Tuberculosis"},{"issue":"2","key":"10.1016\/j.nmni.2024.101533_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Therapeut"},{"key":"10.1016\/j.nmni.2024.101533_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","article-title":"Molecular mechanisms of action of anti-TNF-\u03b1 agents\u2013Comparison among therapeutic TNF-\u03b1 antagonists","volume":"101","author":"Mitoma","year":"2018","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.nmni.2024.101533_bib10","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Present and (foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J Clin Med"},{"issue":"15","key":"10.1016\/j.nmni.2024.101533_bib11","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1\u2013neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib12","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non\u2010anti\u2010TNF\u2010targeted biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediat Inflamm"},{"issue":"5","key":"10.1016\/j.nmni.2024.101533_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"issue":"10","key":"10.1016\/j.nmni.2024.101533_bib14","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"2019","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.nmni.2024.101533_bib15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40257-016-0229-x","article-title":"Body region involvement and quality of life in psoriasis: analysis of a randomized controlled trial of adalimumab","volume":"17","author":"Armstrong","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2015-207511","article-title":"The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression","volume":"75","author":"Atsumi","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.nmni.2024.101533_bib17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.nmni.2024.101533_bib18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.nmni.2024.101533_bib19","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/acr.22556","volume":"67","author":"Bingham","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"9313","key":"10.1016\/j.nmni.2024.101533_bib20","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jdv.13746","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study","volume":"31","author":"Cai","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.nmni.2024.101533_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820938960","article-title":"Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial","volume":"13","author":"Chen","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"10.1016\/j.nmni.2024.101533_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S0929-6646(09)60071-1","article-title":"Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis","volume":"108","author":"Chen","year":"2009","journal-title":"J Formos Med Assoc"},{"issue":"15","key":"10.1016\/j.nmni.2024.101533_bib25","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.nmni.2024.101533_bib26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.nmni.2024.101533_bib27","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bbmt.2009.08.003","article-title":"A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease","volume":"15","author":"Couriel","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.nmni.2024.101533_bib28","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/RHU.0000000000001857","article-title":"Efficacy and safety of intravenous golimumab in patients with ankylosing spondylitis and complete spinal ankylosis: results through week 52 of the GO-ALIVE study","volume":"28","author":"Deodhar","year":"2022","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaad.2017.08.029","article-title":"Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial","volume":"78","author":"Elewski","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.nmni.2024.101533_bib30","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.nmni.2024.101533_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.nmni.2024.101533_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.nmni.2024.101533_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.nmni.2024.101533_bib34","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.nmni.2024.101533_bib35","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3904\/kjim.2016.213","article-title":"Rapid onset of efficacy predicts response to therapy with certolizumab plus methotrexate in patients with active rheumatoid arthritis","volume":"33","author":"Kang","year":"2018","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1136\/annrheumdis-2011-201247","article-title":"Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study","volume":"72","author":"Kavanaugh","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.nmni.2024.101533_bib37","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.nmni.2024.101533_bib38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s13075-014-0467-3","article-title":"Efficacy and safety of pateclizumab (anti-lymphotoxin-\u03b1) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)","volume":"16","author":"Kennedy","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.nmni.2024.101533_bib39","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.nmni.2024.101533_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3899\/jrheum.150712","article-title":"Safety and efficacy of subcutaneous golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: final 5-year results of the GO-FORWARD trial","volume":"43","author":"Keystone","year":"2016","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.nmni.2024.101533_bib41","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1479-8077.2007.00248.x","article-title":"A randomized, double\u2010blind, placebo\u2010controlled, phase III study of the human anti\u2010tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate","volume":"10","author":"Kim","year":"2007","journal-title":"APLAR J Rheumatol"},{"issue":"2","key":"10.1016\/j.nmni.2024.101533_bib43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","article-title":"Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)","volume":"79","author":"Lebwohl","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"9194","key":"10.1016\/j.nmni.2024.101533_bib44","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.nmni.2024.101533_bib45","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/annrheumdis-2015-207596","article-title":"Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study","volume":"75","author":"Maksymowych","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2013-203440","article-title":"Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.nmni.2024.101533_bib48","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-7-5","article-title":"Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients","volume":"9","author":"Pavelka","year":"2020","journal-title":"Drugs Context"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.nmni.2024.101533_bib50","first-page":"1053","article-title":"Long-term benefit of golimumab for patients with moderately to severely active ulcerative colitis: results from the PURSUIT-maintenance extension","volume":"12","author":"Reinisch","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"10","key":"10.1016\/j.nmni.2024.101533_bib51","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3899\/jrheum.180718","article-title":"Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: results through 1 Year of the GO-ALIVE study","volume":"46","author":"Reveille","year":"2019","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.nmni.2024.101533_bib52","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/apt.13291","article-title":"Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis","volume":"42","author":"Rutgeerts","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.nmni.2024.101533_bib53","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib54","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.nmni.2024.101533_bib55","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.nmni.2024.101533_bib57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.nmni.2024.101533_bib58","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/art.39257","article-title":"A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.nmni.2024.101533_bib59","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/ard.2008.101659","article-title":"Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial","volume":"68","author":"Smolen","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.nmni.2024.101533_bib60","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.nmni.2024.101533_bib61","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00535-013-0922-y","article-title":"Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis","volume":"49","author":"Suzuki","year":"2014","journal-title":"J Gastroenterol"},{"issue":"12","key":"10.1016\/j.nmni.2024.101533_bib62","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3899\/jrheum.120541","article-title":"Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial","volume":"39","author":"Tam","year":"2012","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.nmni.2024.101533_bib63","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/annrheumdis-2014-205361","article-title":"OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy","volume":"74","author":"Taylor","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.nmni.2024.101533_bib64","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.nmni.2024.101533_bib65","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13555-021-00520-0","article-title":"Efficacy and safety of certolizumab pegol in Japanese patients with moderate to severe plaque psoriasis: 52-week results","volume":"11","author":"Umezawa","year":"2021","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.nmni.2024.101533_bib66","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy","volume":"46","author":"Van Den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.nmni.2024.101533_bib67","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1002\/art.23141","article-title":"Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis","volume":"56","author":"van der Heijde","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.nmni.2024.101533_bib68","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/art.30372","article-title":"Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial","volume":"63","author":"van Vollenhoven","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.nmni.2024.101533_bib69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.nmni.2024.101533_bib70","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/art.21734","article-title":"The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial","volume":"54","author":"Westhovens","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.nmni.2024.101533_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials","volume":"7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.nmni.2024.101533_bib72","doi-asserted-by":"crossref","first-page":"86","DOI":"10.30978\/TB2021-2-86","article-title":"WHO consolidated guidelines on tuberculosis. Module 1: prevention. Tuberculosis preventive treatment","volume":"2","author":"Organizat","year":"2021","journal-title":"Tuberc Lung Dis HIV Infect"},{"key":"10.1016\/j.nmni.2024.101533_bib73","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijid.2022.02.047","article-title":"The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection","volume":"124","author":"Goletti","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.nmni.2024.101533_bib74","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0079-2021","article-title":"The definition of tuberculosis infection based on the spectrum of tuberculosis disease","volume":"17","author":"Migliori","year":"2021","journal-title":"Breathe"},{"issue":"6","key":"10.1016\/j.nmni.2024.101533_bib75","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/14787210.2018.1483238","article-title":"Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs","volume":"16","author":"Goletti","year":"2018","journal-title":"Expert Review of Anti-Infective Therapy"},{"issue":"3","key":"10.1016\/j.nmni.2024.101533_bib76","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5588\/ijtld.21.0753","article-title":"Clinical standards for the diagnosis, treatment and prevention of TB infection","volume":"26","author":"Migliori","year":"2022","journal-title":"Int J Tubercul Lung Dis"},{"issue":"6","key":"10.1016\/j.nmni.2024.101533_bib77","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/rheumatology\/key023","article-title":"Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"57","author":"Rutherford","year":"2018","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.nmni.2024.101533_bib78","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/aps.2010.134","article-title":"Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis","volume":"31","author":"Jin","year":"2010","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"10.1016\/j.nmni.2024.101533_bib79","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/qjmed\/hcq152","article-title":"TNF-\u03b1 antagonists beyond approved indications: stories of success and prospects for the future","volume":"103","author":"Karampetsou","year":"2010","journal-title":"QJM: Int J Med"},{"issue":"9","key":"10.1016\/j.nmni.2024.101533_bib80","doi-asserted-by":"crossref","first-page":"8187","DOI":"10.3390\/ijms24098187","article-title":"Focus on anti-tumour necrosis factor (TNF)-\u03b1-Related autoimmune diseases","volume":"24","author":"Lopetuso","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.nmni.2024.101533_bib81","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00913-2018","article-title":"Tuberculosis after a borderline QuantiFERON result during screening before infliximab","volume":"52","author":"Uzorka","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmni.2024.101533_bib82","series-title":"Tuberculosis: integrated studies for a complex disease","first-page":"697","article-title":"Anti-tumor necrosis factor-\u03b1 antagonists and tuberculosis","author":"Lim","year":"2023"},{"key":"10.1016\/j.nmni.2024.101533_bib83","first-page":"1491","article-title":"Risk of cancer, tuberculosis and serious infections in patients with ankylosing spondylitis, psoriatic arthritis, and psoriasis treated with IL-17 and TNF-\u03b1 inhibitors: a nationwide nested case-control analysis","volume":"41","author":"Kim","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nmni.2024.101533_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.948652","article-title":"Clinical characteristics and related influencing factors of common rheumatic diseases concomitant with tuberculosis","volume":"10","author":"Tang","year":"2023","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.nmni.2024.101533_bib85","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","article-title":"Infections associated with tumor necrosis factor-\u03b1 antagonists","volume":"84","author":"Crum","year":"2005","journal-title":"Medicine"},{"key":"10.1016\/j.nmni.2024.101533_bib86","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/0378-6323.115526","article-title":"Tumor necrosis factor-\u03b1 antagonists: side effects and their management","volume":"79","author":"Dogra","year":"2013","journal-title":"Indian J Dermatol, Venereol Leprol"},{"issue":"4","key":"10.1016\/j.nmni.2024.101533_bib87","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13913","article-title":"Prevalence and management of tuberculosis infection in Apulian rheumatologic patients treated with biologics: an observational cohort 10\u2010year study from the BIOPURE registry","volume":"53","author":"Fornaro","year":"2023","journal-title":"Eur J Clin Invest"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297524003172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297524003172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:41:04Z","timestamp":1762598464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2052297524003172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":87,"alternative-id":["S2052297524003172"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2024.101533","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of tuberculosis disease in patients receiving TNF-\u03b1 antagonist therapy: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2024.101533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101533"}}